Treating EGFR Exon 20 Insertion+ mNSCLC: Equipping Oncology Nurses to Optimize Care

Join us live in Anaheim or online for an expert-led CE-certified satellite symposium where expert faculty will discuss the evolving treatment landscape for patients with advanced NSCLC and EGFR exon 20 insertion mutations via a series of patient cases. This event will offer attendees the opportunity to have their questions answered by the expert panel.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. Additionally, in accordance with ONS’ COVID-19 protocols, all in-person learners will be asked to wear a mask and present their ONS conference badge -OR- proof of vaccination AND Government-issued ID to gain admittance to Treating EGFR Exon 20 Insertion+ mNSCLC: Equipping Oncology Nurses to Optimize Care.

For more information on ONS’ vaccination and mask requirements, please visit: ONS’ website

*If you do not have your vaccination record card, find out other ways to verify you have been vaccinated.

Meeting space has been assigned to provide a Symposium supported by Clinical Care Options, LLC during the Oncology Nursing Society’s (ONS) 47th Annual Congress, April 28 – May 1, 2022 in Anaheim, CA. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.

Agenda

  • Identification of patients with EGFR exon 20 insertion–positive NSCLC
  • Overview of the latest clinical data on new and emerging agents targeting EGFR exon 20 insertions
  • Understanding the biology and pathology of the toxicity profile associated with agents targeting EGFR
  • Monitoring and management strategies for AEs associated with newer EGFR-targeted agents

Events

Date / Time
Event Details

Faculty

Faculty
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Instructor
Adult Specialty Program
Yale University School of Nursing
Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

Faculty
Matthew Gubens, MD, MS

Associate Professor
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and clinical nurse specialists to understand and explain clinical data on recently approved therapies targeting EGFR exon 20 insertion mutations and the differences in monitoring and managing AEs for their patients with lung cancer receiving these therapies.

Target Audience
This educational program is intended for oncology nurses, nurse practitioners, and clinical nurse specialists who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the significance of EGFR exon 20 insertions with appropriate patients with lung cancer
  • Evaluate the clinical data of new and emerging agents targeting EGFR exon 20 insertion mutations
  • Describe the biology and pathology of the EGFR-targeting toxicity profile
  • Develop care plans for monitoring and managing agent-specific adverse events for the treatment of patients with EGFR exon 20 insertion NSCLC receiving these new therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.